Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of KRP-AM1977X (lascufloxacin) tissue penetration in otorhinolaryngologic tissues
jRCT2080222747Phase 1Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lascufloxacin in bacterial disease, sponsored by Kyorin Pharmaceutical. Primary endpoints: AM-1977 concentration in otorhinolaryngologic tissues and Safety and tolerability of KRP-AM1977X. Started Feb 2015; status: completed.
02
Drugs
lascufloxacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on jRCT2080222747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222747.